574705-92-3

Basic information

• Product Name: Pitavastatin Sodium
• Synonyms: Pitavastatin Sodium;(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt
• CAS NO: 574705-92-3
• Molecular Formula: C₂₅H₂₃FNO₄*Na
• Molecular Weight: 443.4425932
• Mol File: 574705-92-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pitavastatin Sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Pitavastatin Sodium(574705-92-3)
• EPA Substance Registry System: Pitavastatin Sodium(574705-92-3)

Safety Data

• Hazardous Substances Data: 574705-92-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pitavastatin Sodium is used as a cholesterol-lowering agent for individuals with high cholesterol levels. It is prescribed to patients at risk of heart disease or stroke, helping to improve overall cholesterol profiles by reducing low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL).
Used in Cardiovascular Health Management:
Pitavastatin Sodium is employed as a preventive measure in cardiovascular health management. By lowering LDL cholesterol and raising HDL cholesterol, it helps to reduce the risk of atherosclerosis and other cardiovascular complications, thus playing a crucial role in the prevention and treatment of heart disease and stroke.

Upstream product

• 167073-19-0 (E)-(3R,5S)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid ethyl ester 
• 765-43-5 Cyclopropyl methyl ketone 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 
• 121659-86-7 methyl 4-(4'-fluorophenyl)-2-cyclopropylquinoline-3-carboxylate 
• 147489-06-3 (4R,6S)-(E)-{6-[2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid tert-butyl ester 
• 154057-58-6 <2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl>methyltriphenylphosphonium bromide 
• 586966-54-3 (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid tert-butyl ester 
• 1068433-24-8 (4R,6S)-4-(tert-butyldimethylsilyloxy)-6-(dihydroxymethyl)tetrahydro-2H-pyran-2-one 
• 1391833-13-8 [2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl trifluoroacetate 
• 1391833-12-7 (4R,6S)-4-{[tert-butyl(dimethyl)silyl]oxy}-6-{(E)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]vinyl}tetrahydro-2H-pyran-2-one 
• 1391833-14-9 tributyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium trifluoroacetate 
• 1391833-16-1 tricyclohexyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium bromide 
• 1391833-18-3 tricyclohexyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium trifluoroacetate 

Downstream Products

• 147526-32-7 pitavastatin calcium salt 

Relevant articles and documents

Nitrate NO donor-type statin derivatives and preparation method thereof

The invention discloses nitrate NO donor-type statin derivatives and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The nitrate NO donor-type statinderivatives adopt a structural formula shown as a genera

Furoxan azoxyNO donor type tadine derivative and preparation method thereof (by machine translation)

The invention discloses a furoxan azoxyNO donor type tadine derivative and a preparation method, and belongs to the technical field of chemical synthesis of medicines: the invention has the following structural formula shown in the general formula. Wherein. In addition, coumaric acid is selected as a connecting base, so that the curative effect; in addition, the compound disclosed by the invention can effectively release NO, and beneficial attempts are made for development of NO donor anti-atherosclerotic drugs in an external mode, and the method has the advantages of effectively improving the curative effect of drugs. 4 - R1 R2 (by machine translation)

3,5-dihydroxyhept-6-enoic acid derivative preparation method

The invention relates to a preparation method of 3, 5-dihydroxy-6-heptenoic acid derivatives. The preparation method comprises the steps of hydrolyzing crude statin ester to form a water-soluble alkali metal salt, extracting by using a solvent to remove impurities which cannot be dissolved into water, and converting at high yield to form ester with relatively high purity; then, purifying the ester by using a recrystallization way to obtain pure statin ester; and finally, converting the pure statin ester at high yield to form statin calcium, namely the 3, 5-dihydroxy-6-heptenoic acid derivatives. The 3, 5-dihydroxy-6-heptenoic acid derivatives, namely rosuvastatin calcium and pitavastatin calcium, synthesized by using the preparation method are high in purity and total yield, relatively low in cost and beneficial to mass production.

Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

The use of a lactonized statin side-chain precursor in a concise and efficient assembly of pitavastatin

A concise and simple synthetic route to pitavastatin is described. The approach involves a highly stereoselective Wittig olefination reaction between a lactonized statin side-chain precursor and the triphenylphosphonium bromide salt of the corresponding quinoline heterocyclic core. The necessary O-tert-butyl(dimethyl)silyl-protected pitavastatin lactone was obtained in 75% yield and high purity by simple crystallization from aqueous methanol. Subsequent deprotection, hydrolysis, and cation exchange in a one-pot operation provided pitavastatin calcium in 93% yield. Georg Thieme Verlag Stuttgart · New York.

Process for the manufacture of organic compounds

A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(